![]() SEQENS SEQENS (previously known as Novacap) is a company specializing in pharmaceutical synthesis and specialty ingredients. | ![]() Sartorius Stedim Biotech Sartorius Stedim Biotech is a provider of products and services for the development, quality assurance, and production processes of the biopharmaceutical industry. | ![]() Dottikon Dottikon ES Holding is a company that manufactures active pharmaceutical ingredients, intermediates, and performance chemicals. | ||
Founding Date | Founding Date 2003 | Founding Date 2007 | Founding Date 1913 | Founding Date 1982 |
Type | Type Private | Type Public | Type Public | Type Private |
Tags | ||||
Locations | Locations Écully, FR HQ Saint Jean Sur Richelieu, CA Taizhou Shi, CN Zhenjiang, CN Turku, FI Bourgoin Jallieu, FR see more | Locations Aubagne, FR HQ Jaipur, IN Bohemia, US | Locations Dottikon, CH HQ | Locations Newton, US HQ Olivos, AR Vicente López, AR Brisbane, AU Macquarie Park, AU Wavre, BE Sao Paulo, BR see more |
Employees | Employees 3,300 | Employees 9,961 | Employees 770 | Employees 20,806 |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €3b (FY, 2025) | Revenue (est.) CHF428.4m (FY, 2026) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods €1.3b (FY, 2025) | Cost of goods CHF155.8m (FY, 2026) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €1.7b (FY, 2025) | Gross profit CHF274.4m (FY, 2026) | Gross profit N/A |
Net income | Net income N/A | Net income €265.9m (FY, 2025) | Net income CHF103.6m (FY, 2026) | Net income N/A |

Sartorius Stedim Biotech is a provider of products and services for the development, quality assurance, and production processes of the biopharmaceutical industry.
View company
Dottikon ES Holding is a company that manufactures active pharmaceutical ingredients, intermediates, and performance chemicals.
View company
Parexel International (MA) is a clinical research organization.
View company